Since its foundation in 2005, the Company has developed and patented a unique biomaterial with applications in gastroenterology and urology. Vysera’s biomaterial is:

• Biomimetic: can mimic the mechanical properties of soft biological tissues.
• Biocompatible: it does not invoke an inflammatory response.
• Biostable: it does not degrade in the gastrointestinal or urinary tracts.
• Biodurable: it does not lose form or function once implanted.

Vysera’s first product, an esophageal stent valve for the palliative treatment of esophageal cancer, was licensed to Merit Medical Systems Inc., (NASDAQ: MMSI) in late 2009. This first-in-class product will be marketed directly by MMSI, and represents the first commercialization of Vysera’s technology.

Vysera has a seasoned management team with long experience in bringing new technology and products to commercial realization. The Company’s Clinical Advisory Board is drawn from leading clinicians in the fields of gastroenterology and urology, and it has collaborative partnerships with the Mayo Clinic (a shareholder) and Harvard Medical School. The Company is developing novel devices for obesity and urinary incontinence based on the same core technology.